These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 36394981)

  • 1. Clinical usefulness of circulating tumor markers.
    Filella X; Rodríguez-Garcia M; Fernández-Galán E
    Clin Chem Lab Med; 2023 Apr; 61(5):895-905. PubMed ID: 36394981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High Expression of BCAR1 by Circulating Tumor Cells and Tumor Tissues Is Predictive of a Poor Prognosis of Early-Stage Lung Adenocarcinoma Potentially Due to Regulation of Epithelial-Mesenchymal Transition.
    Jiang S; Mao C; Jiang B; Tan Q; Deng B
    Technol Cancer Res Treat; 2020; 19():1533033820983086. PubMed ID: 33334252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of different methods for the detection of minimal residual disease in blood and bone marrow of patients with primary breast cancer: importance for clinical use?
    Kasimir-Bauer S; Oberhoff C; Sliwinska K; Neumann R; Schindler AE; Seeber S
    Breast Cancer Res Treat; 2001 Sep; 69(2):123-32. PubMed ID: 11759818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum CYFRA 21-1 is one of the most reliable tumor markers for breast carcinoma.
    Nakata B; Ogawa Y; Ishikawa T; Ikeda K; Kato Y; Nishino H; Hirakawa K
    Cancer; 2000 Sep; 89(6):1285-90. PubMed ID: 11002224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Circulating "tumor markers" in gastrointestinal tumors].
    Borlinghaus P; Lamerz R
    Leber Magen Darm; 1991 Sep; 21(5):199-202, 205-6. PubMed ID: 1758235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Early prediction of treatment response to high-dose chemotherapy in patients with relapsed germ cell tumors using [18F]FDG-PET, CT or MRI, and tumor marker].
    Pfannenberg AC; Oechsle K; Kollmannsberger C; Dohmen BM; Bokemeyer C; Bares R; Vontheim R; Claussen CD
    Rofo; 2004 Jan; 176(1):76-84. PubMed ID: 14712410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preliminary investigation of the clinical significance of detecting circulating tumor cells enriched from lung cancer patients.
    Wu C; Hao H; Li L; Zhou X; Guo Z; Zhang L; Zhang X; Zhong W; Guo H; Bremner RM; Lin P
    J Thorac Oncol; 2009 Jan; 4(1):30-6. PubMed ID: 19096303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of immune cell markers and tumor markers in patients with cervical cancer.
    Zhang L; Zhang H; Huang Y; Xi X; Sun Y
    Int J Gynecol Cancer; 2020 Jul; 30(7):969-974. PubMed ID: 32518078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatic mutations in plasma cell-free DNA are diagnostic markers for esophageal squamous cell carcinoma recurrence.
    Ueda M; Iguchi T; Masuda T; Nakahara Y; Hirata H; Uchi R; Niida A; Momose K; Sakimura S; Chiba K; Eguchi H; Ito S; Sugimachi K; Yamasaki M; Suzuki Y; Miyano S; Doki Y; Mori M; Mimori K
    Oncotarget; 2016 Sep; 7(38):62280-62291. PubMed ID: 27556701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive Liquid Profiling of Circulating Tumor DNA and Protein Biomarkers in Long-Term Follow-Up Patients with Hepatocellular Carcinoma.
    Cai Z; Chen G; Zeng Y; Dong X; Li Z; Huang Y; Xin F; Qiu L; Xu H; Zhang W; Su X; Liu X; Liu J
    Clin Cancer Res; 2019 Sep; 25(17):5284-5294. PubMed ID: 31217202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating tumor cells and their advances to promote cancer metastasis and relapse, with focus on glioblastoma multiforme.
    Chistiakov DA; Chekhonin VP
    Exp Mol Pathol; 2018 Oct; 105(2):166-174. PubMed ID: 30028961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current concepts of tumor markers in bladder cancer.
    Droller MJ
    Urol Clin North Am; 2002 Feb; 29(1):229-34. PubMed ID: 12109349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-operative plasma cell-free circulating tumor DNA and serum protein tumor markers as predictors of lung adenocarcinoma recurrence.
    Isaksson S; George AM; Jönsson M; Cirenajwis H; Jönsson P; Bendahl PO; Brunnström H; Staaf J; Saal LH; Planck M
    Acta Oncol; 2019 Aug; 58(8):1079-1086. PubMed ID: 31230502
    [No Abstract]   [Full Text] [Related]  

  • 14. CT combined with tumor markers in the diagnosis and prognosis of hepatocellular carcinoma.
    Huang X; Li J; Wang F; Hao M
    J BUON; 2018; 23(4):985-991. PubMed ID: 30358203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Auxiliary Diagnostic Value of Tumor Markers in the Cerebrospinal Fluid and Blood for Leptomeningeal Metastasis from Non-small Cell Lung Cancer].
    Lin Y; Li H; Huang M; Yin Z; Wu J
    Zhongguo Fei Ai Za Zhi; 2020 Jun; 23(6):516-525. PubMed ID: 32517459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma MMP-9 (92 kDa-MMP) activity is useful in the follow-up and in the assessment of prognosis in breast cancer patients.
    Ranuncolo SM; Armanasco E; Cresta C; Bal De Kier Joffe E; Puricelli L
    Int J Cancer; 2003 Sep; 106(5):745-51. PubMed ID: 12866035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment monitoring of patients with epithelial ovarian cancer using invasive circulating tumor cells (iCTCs).
    Pearl ML; Dong H; Tulley S; Zhao Q; Golightly M; Zucker S; Chen WT
    Gynecol Oncol; 2015 May; 137(2):229-38. PubMed ID: 25769657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of circulating c-met messenger RNA is significantly correlated with nodal stage and early recurrence in non-small cell lung cancer.
    Cheng TL; Chang MY; Huang SY; Sheu CC; Kao EL; Cheng YJ; Chong IW
    Chest; 2005 Sep; 128(3):1453-60. PubMed ID: 16162743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.